Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QMF149 Twisthaler · 1 trial · 1 indication
Defined as the number of days from start of treatment up to the first date when an asthma exacerbation becomes serious. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.
| Arm | Type | Description |
|---|---|---|
| QMF149 Twisthaler® 500/400 | EXPERIMENTAL | QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD) |
| Mometasone Twisthaler® | ACTIVE_COMPARATOR | Mometasone Twisthaler®, 400 µg QD |
| Name | Type | Description |
|---|---|---|
| QMF149 Twisthaler® | DRUG | Once daily via multi-dose dry-powder inhaler |
| Mometasone Twisthaler® | DRUG | Once daily via multi-dose dry-powder inhaler |
Inclusion Criteria: * Patients with a documented diagnosis of persistent asthma and who were currently treated with or qualified for treatment with both ICS and long-acting beta2-agonist (LABA) combination * Patients demonstrating an increase in forced expiration volume in 1 second (FEV1) of ≥ 12% ...
QMF149 Twisthaler is an investigational small molecule being developed for the treatment of asthma. It is delivered via the Twisthaler device. As of the available data, it is in Phase 2 clinical development and is not approved by regulatory authorities.
QMF149 Twisthaler is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for asthma.
QMF149 Twisthaler is in Phase 2 clinical development. It is an investigational drug for asthma and has not received regulatory approval. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
QMF149 Twisthaler has been studied in one completed Phase 2 clinical trial, identified as NCT00941798. This trial, titled "Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma," enrolled 2,283 participants across multiple countries including the United States, Brazil, and India.
QMF149 Twisthaler is the specific name of the drug product developed by Novartis. The Twisthaler refers to the inhalation device used to deliver the medication. No alternative drug names have been reported in the available clinical trial information.